Sunday 18 October 2026
Export DHAI’s income statement to Excel — free account
DIH Holding US, Inc.
DHAI Healthcare Medical Devices
DIH Holding US, Inc.’s revenue for fiscal 2025 (year ended March 2025) was $62.9 million, down 2.50% from fiscal 2024. In the quarter to March 2025, revenue fell 30.7%, EPS grew 30.0% and free cash flow fell 167.9%, each against the same quarter a year earlier.
0.00
0.00
NaN
Follow DHAI
| Mar '25 | Mar '24 | Dec '23 | Mar '23 | Dec '22 | Mar '22 | Dec '21 | Mar '21 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | — | — | — | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | — | 23.52 | — | — | — | — | — |
P/S ratio |
0.01 | 0.00 | — | 0.00 | — | — | — | — | — |
Altman Z-Score |
(1.78) | (0.41) | — | 2.72 | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(13.04) | (7.49) | — | (5.47) | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.19 | — | 0.00 | — | — | — | — | — |
P/Operating CF |
(0.10) | 0.23 | — | (407.23) | — | — | — | — | — |
Beneish M-Score |
(3.91) | (4.17) | — | — | — | — | — | — | — |
P/B ratio |
0.00 | 0.00 | — | 0.00 | — | — | — | — | — |
Price to Tangible BV |
0.00 | 0.00 | — | 0.00 | — | — | — | — | — |
EV/Sales |
0.15 | 0.00 | — | 0.00 | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | — | 0.00 | — | — | — | — | — |
EV/Operating CF |
(2.28) | 1.69 | — | (45.22) | — | — | — | — | — |
EV/FCF |
(2.02) | 1.77 | — | (45.22) | — | — | — | — | — |
Quick Ratio |
0.20 | 0.31 | 0.00 | 0.42 | 0.44 | 0.00 | 0.18 | — | — |
Current Ratio |
0.49 | 0.60 | 0.00 | 0.69 | 1.09 | 2.07 | 0.18 | — | — |
Net Debt/EBITDA |
(1.47) | (3.56) | (0.56) | 18.23 | 0.11 | (0.14) | (17.74) | 0.00 | — |
Debt/Assets |
41.33% | 32.06% | 3.40% | 54.44% | 0.00% | 36.32% | 65.13% | 0.00% | 0.00% |
Debt/Equity |
(0.30) | (0.35) | (0.17) | (0.60) | 0.00 | 9.96 | 16.19 | — | — |
Asset Turnover |
2.01 | 1.37 | 0.00 | 0.45 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.48 | (0.61) | (1.08) | (5.42) | (0.17) | (0.58) | 0.00 | 0.00 | — |
Capex/Depreciation |
(0.64) | (0.67) | — | (2.20) | — | 0.00 | — | — | — |
Interest Coverage |
(22.16) | (3.77) | — | 2.56 | — | — | — | — | — |
| 24.90% | 37.95% | (3.13%) | 5.54% | (173.87%) | 33,523.86% | 0.00% | 0.00% | — | |
| (27.77%) | (17.89%) | 1.42% | (0.85%) | 6.35% | 1,267.84% | (5.36%) | 0.00% | — | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (398.58%) | (3.25%) | 0.00% | — |
Return on Tangible Assets |
41.04% | 48.61% | (13.90%) | 9.42% | 17,153.77% | 2,530.34% | 3.42% | 0.00% | — |
Average Days of Receivables |
39.00 | 61.62 | — | 83.60 | — | — | — | — | — |
Research and Development Expense of Revenue |
11.29% | 10.25% | — | 12.80% | — | 0.00% | — | — | — |
Selling, General and Administrative Expense of Revenue |
47.69% | 39.98% | — | 42.47% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.72% | 0.00% | — | 0.00% | — | — | — | — | — |
Graham Net Nets |
(129.22) | (34.28) | — | (1.24) | — | — | — | — | — |
Graham Number |
301.41 | 404.24 | — | 0.00 | — | — | — | — | — |
Earnings Yield |
(107.60%) | (33.04%) | — | 4.25% | — | — | — | — | — |
Free Cash Flow Yield |
(1,415.54%) | 538.21% | — | (2.22%) | — | — | — | — | — |
Revenue per Share |
1,099.02 | 1,527.80 | 0.00 | 54.06 | 0.00 | — | 0.00 | — | — |
Operating CF per Share |
(72.45) | 123.03 | (3.24) | 5.50 | (5.16) | 0.00 | 0.00 | — | — |
Capex per Share |
(9.37) | (4.79) | 0.00 | (0.14) | 0.00 | 0.00 | 0.00 | — | — |
Free Cash Flow per Share |
(81.82) | 118.25 | (3.24) | 5.36 | (5.16) | 0.00 | 0.00 | — | — |
Cash per Share |
33.90 | 76.42 | 0.06 | 3.18 | 0.90 | — | 0.33 | — | — |
Shareholders Equity per Share |
(649.21) | (771.23) | (55.79) | (28.95) | (35.85) | 0.00 | 0.08 | — | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Book value per Share |
(649.21) | (771.23) | (55.79) | (28.95) | (35.85) | 0.00 | 0.08 | — | — |
Free Cash Flow |
(4.68) | 4.99 | (0.69) | 5.36 | (1.10) | (3.84) | 0.00 | — | — |
Working Capital |
(21.69) | (17.90) | (4.61) | (11.51) | 0.04 | 0.26 | (0.29) | — | — |
Capital Expenditures |
(0.54) | (0.20) | — | (0.14) | — | 0.00 | — | — | — |
Net Current Asset Value |
(42.72) | (41.22) | (70.59) | (35.47) | (214.50) | 0.26 | (0.29) | — | — |
EV/EBIT |
0.00 | 0.00 | — | 0.00 | — | — | — | — | — |
Capex to Sales |
0.01 | 0.00 | — | 0.00 | — | 0.00 | — | — | — |
Price to Operating Income |
0.00 | 0.00 | — | 0.00 | — | — | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
1.52 | 0.57 | — | 0.09 | — | 0.00 | — | — | — |
Cash ROIC |
19.39% | (27.93%) | 6.99% | (63.18%) | 14.75% | (1,437.92%) | 0.00% | — | — |
Accounts Receivable Turnover |
7.14 | 5.54 | — | 0.00 | — | — | — | — | — |
Accounts Payable Turnover |
8.00 | 10.43 | 0.00 | 21.15 | 0.00 | — | — | — | — |
Inventory Turnover |
4.12 | 5.47 | — | 0.00 | — | — | — | — | — |
Average Days of Payables |
39.97 | 45.28 | 0.00 | 34.05 | 0.00 | — | 0.00 | — | — |
Days of Inventory on Hand |
83.93 | 82.36 | — | 75.41 | — | — | — | — | — |
Average Receivables |
8.80 | 11.63 | — | — | — | — | — | — | — |
Average Payables |
3.83 | 3.33 | 2.27 | 1.11 | 0.02 | — | — | — | — |
Average Inventory |
7.44 | 6.34 | — | — | — | — | — | — | — |
Average Assets |
31.24 | 47.20 | 45.22 | 119.57 | 104.01 | 0.52 | 0.19 | 0.00 | — |
Average Common Equity |
(34.84) | (22.25) | (20.45) | (18.29) | (3.80) | 0.02 | — | — | — |
Columns are period end dates · fundamentals updated 28 Sep 2026